Nesina
(Alogliptin)ApprovedSmall molecule
TakedaAlogliptin is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release more insulin when blood sugar is high.[2] Nesina is currently approved and in use across 2 indications[4].[1]
Nesina is one of 89 small molecule programs targeting Diabetes Mellitus. It is currently in Approved.
2
Indications
59
Total Trials
1
Active Trials
88
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Nesina
TakedaApproved
DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
Elecoglipron
AstraZenecaPhase 3
Imeglimin
PPoxel SA
Phase 3
Dorzagliatin
HHua Medicine Limited
Phase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes22 trials
Show 19 more trials
The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
Completed·—·N/A·NCT02798172·81 enrolled
Type 2 Diabetes Mellitus19 trials
Show 16 more trials
Combination Therapy2 trials
Type 2 Diabetic Patients2 trials
12 more indications
Acute Coronary Syndrome1 trial
Pancreatic1 trial
Effects of Alogliptin on Pancreatic Beta Cell Function
Unknown status·—·N/A·NCT01303055·80 enrolled
Efficacy and Safety1 trial
ART1 trial
Diabetes Mellitus1 trial
Metformin1 trial
Regulatory
FDA Approval Timeline[5]
Jan 25, 2013
NESINA
NDA NDA022271
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Nesina drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alogliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Nesina. U.S. Food & Drug Administration.
- [7]